Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

CMC Consulting for Advanced Therapy Medicinal Products (ATMPs) in the European Union

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

CMC Consulting for Advanced Therapy Medicinal Products (ATMPs) in the European Union

CMC Consulting for Advanced Therapy Medicinal Products in Europe

CELL & GENE | RNA | BIOLOGICS

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

A robust Chemistry, Manufacturing, and Controls (CMC) strategy is the foundation for successful Investigational Medicinal Product Dossier (IMPD) submissions for viral vector-based Advanced Therapy Medicinal Products (ATMPs). This requires a phase-appropriate approach that aligns vector production, process development, and analytical characterization with the specific expectations of European regulatory bodies like the MHRA. Our approach focuses on building a comprehensive data package that anticipates regulatory scrutiny, minimizes clinical risk, and supports an 18-24 month timeline to Clinical Trial Authorisation (CTA).

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Frequently Asked Questions

    What is the primary focus of ATMP CMC consulting for EU submissions?

    The focus is on developing a scientifically sound manufacturing process and a corresponding analytical control strategy. This ensures product quality, consistency, and safety, forming the core of the IMPD submission required for clinical trials in Europe.

    How does plasmid quality impact the final viral vector product?

    The quality of the starting plasmid DNA directly influences the purity, potency, and safety profile of the final AAV, lentivirus, or adenovirus vector. A well-characterized plasmid master cell bank is a prerequisite for a compliant GxP manufacturing campaign.

    Which analytical assays are most important for an IMPD?

    Key assays include those for vector genome titer, capsid content, purity (e.g., empty/full capsid ratio), identity, and potency. A phase-appropriate qualification or validation of these assays is expected by European regulators.

    How early should sponsors engage in CMC consulting?

    Sponsors should engage in CMC consulting prior to final candidate selection. Early planning ensures that the vector design, production platform (e.g., adherent vs. AAV scalable suspension), and analytical development strategy are aligned for long-term clinical and commercial viability.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Aligning Vector Manufacturing with European Regulatory Expectations

Navigating the regulatory pathway for viral vectors in Europe requires a purpose-built CMC strategy. Successful IMPD submissions are built upon data-driven plans tailored to the specific vector modality, such as an AAV serotype or lentiviral construct, and its target indication. The objective is to demonstrate a comprehensive understanding of the product and a controlled, reproducible manufacturing process.

Our scientific leadership provides the necessary guidance to build this foundation. We focus on key areas that are subject to intense regulatory review:

  • Plasmid DNA Services: Establishing the quality and traceability of starting materials.

  • Process Development: Defining a scalable production process, for either adherent or suspension platforms, that ensures consistency from preclinical batches to GxP manufacturing.

  • Analytical Strategy: Developing and qualifying a robust panel of assays to characterize the vector, confirming its identity, strength, quality, and purity.

This guidance is delivered through a collaborative partnership model, providing sponsors with access to integrated scientific and technical expertise covering all aspects of vector production and analytics.

From Vector Biology to a Defensible Data Package

A deep understanding of vector biology is required to build a compelling CMC narrative. For instance, insights into the mechanisms of vector immunogenicity, such as the role of Toll-like receptor 9 (TLR9) signaling in adaptive immune responses to AAV (PMID: 31703913), directly inform the analytical control strategy. Characterizing product-related impurities that could potentiate these responses becomes a central part of the quality assessment.

This scientific rationale is integrated into every stage of development. Drawing from the principles of programs designed to support translational research (PMID: 23692378), our consulting provides a clear framework. This ensures that the data generated for vector characterization directly supports the product’s quality and safety profile for first-in-human studies. This approach provides strategic CMC guidance for regulatory success.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Featured Video: Franklin Biolabs Facility Overview

Our >100,000 sq ft of animal housing and specialized laboratory space provides the infrastructure to execute on these complex CMC strategies.

Technical Visualization: ATMP CMC Consulting Pathway for IMPD Submission

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities